Area of research
Immunology · Oncology
Research interest
Research interests include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Bone fractures and treatments, and Hip disorders and treatments.
Sequential STING and CD40 agonism drives massive expansion of tumor-specific T cells in liposomal peptide vaccines.
Clinical practice and implications of biomarker testing in biliary tract cancer: An observational study
A preclinical model for the identification of therapeutically active transgenes in local cancer immunotherapy.
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort.
Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity.
Radial head distalisation with an external ring fixator as a therapy option in children with chronic posttraumatic radiocapitellar dislocations
Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience.
Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Prospects and Challenges for T Cell-Based Therapies of HCC.
Chemotherapy and Hepatic Steatosis: Impact on Postoperative Morbidity and Survival after Liver Resection for Colorectal Liver Metastases.
Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer
Multimodale Therapie des hepatozellulären Karzinoms
[Multimodal treatment of hepatocellular carcinoma].
[Management of benign liver tumors].
Live vaccines-a short-cut to cancer viro-immunotherapy.
[Liver tumors-diagnostics and treatment in 2020].
[Best supportive care in a young patient with locally advanced MSI-high colon cancer?]
Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.
Choledochal Cyst and Malignancy: A Plea for Lifelong Follow-Up.
HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection.
HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
Choledochal Cyst and Malignancy: A Plea for Lifelong Follow-Up
Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer
CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations
Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells
Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer
The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma